Ibex Investors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Ibex Investors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-28,252	Closed	-$216K	–	167
2018 Q3	$216K	Buy	+28,252	New	+$190K	0.12%	72

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

VMI

VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Ibex Investors's BCRX Position: Q4 2018 in Review

Ibex Investors sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2018, closing a stake of 28,252 shares — an estimated $216K sold.

Ibex Investors first reported a position in BCRX in Q3 2018 and held it in 1 quarter. The position peaked at $216K in Q3 2018. 123 funds tracked by Wall St. Rank hold BCRX as of Q4 2018.

Ibex Investors reported no remaining BioCryst Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Ibex Investors sold 28,252 BioCryst Pharmaceuticals shares in Q4 2018, an estimated $216K.
Ibex Investors first reported a position in BioCryst Pharmaceuticals in Q3 2018 and held it in 1 quarter.
Ibex Investors's BioCryst Pharmaceuticals position peaked at $216K in Q3 2018.
123 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2018.

Based on Ibex Investors's 13F filing for Q4 2018, filed 13 Feb 2019.